Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 75

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 75
---
ibart (formerly CBP-201) or any other future product candidates (collectively, our “Product Candidates”) through regulatory approvals, and we will need additional capital to complete                                                       
 their development and commercialization.                                                                                                                                                                                                                 |

3

| • |     | Raising additional capital may cause substantial dilution to our shareholders, including holders of our ADSs, 
 restrict our operations or require us to relinquish rights to our technologies or Product Candidates.         |

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

| • |     | Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur                                                
 unforeseen costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our Product Candidates. |

| • |     | We depend on enrollment of patients in our clinical trials for our Product Candidates. If we experience delays                                                                                       
 or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected. |

| • |     | Our Product Candidates may be associated with serious adverse events or undesirable side effects or have other                                                                               
 properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. |

| • |     | We have conducted and may continue to conduct clinical trials for our Product Candidates in international      
 sites, and the applicable regulatory authority may not accept data from trials conducted in foreign locations. |

| • |     | Interim, “top-line” or preliminary data from our clinical                                                                                                                                                           
 trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. |

| • |     | We may attempt to secure approval from the U.S. Food and Drug Administration (the “FDA”), the                                                                                                                                                       
 National Medical Products Administration (“NMPA”) or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical        
 trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, the NMPA or comparable foreign regulatory    
 authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA,